132 related articles for article (PubMed ID: 38307459)
21. Outcomes in Relapsed Graves' Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment.
Villagelin D; Romaldini JH; Santos RB; Milkos AB; Ward LS
Thyroid; 2015 Dec; 25(12):1282-90. PubMed ID: 26414885
[TBL] [Abstract][Full Text] [Related]
22. Correlation between thyroid volume and humoral thyroid autoimmunity after radioiodine therapy in Graves' disease.
Sawicka N; Sowiński J
Endokrynol Pol; 2012; 63(1):10-3. PubMed ID: 22378091
[TBL] [Abstract][Full Text] [Related]
23. Thyroid Isthmus Length and Iodine Turnover as Predictors of Successful Radioactive Iodine Therapy in Patients with Graves' Disease.
Park SH; Hwang S; Han S; Shin DY; Lee EJ
Int J Endocrinol; 2017; 2017():7354673. PubMed ID: 29358949
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant lithium improves the efficacy of radioactive iodine treatment in Graves' and toxic nodular disease.
Martin NM; Patel M; Nijher GM; Misra S; Murphy E; Meeran K
Clin Endocrinol (Oxf); 2012 Oct; 77(4):621-7. PubMed ID: 22443227
[TBL] [Abstract][Full Text] [Related]
25. Use of cold iodine in patients with Graves' disease: observations from a clinical practice.
Hao ST; Reasner CA; Becker RA
Endocr Pract; 2001; 7(6):438-42. PubMed ID: 11747279
[TBL] [Abstract][Full Text] [Related]
26. Age moderates the associations between TRAbs, free T3 and outcomes of Graves' disease patients with radioactive iodine treatment.
Lu L; Gao C; Zhang N
Clin Endocrinol (Oxf); 2021 Feb; 94(2):303-309. PubMed ID: 32734611
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcome and prognostic factors of single-dose Radioiodine Therapy in patients with Graves' disease.
Yang YT; Chen JF; Tung SC; Kuo MC; Weng SW; Chou CK; Shen FC; Chang CM; Tsai CJ; Taso CF; Wang PW
J Formos Med Assoc; 2020 May; 119(5):925-932. PubMed ID: 32057544
[TBL] [Abstract][Full Text] [Related]
28. Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves' Disease: A Pilot Study.
Lu JY; Chen KH; Shih SR; Wen FY; Wu WC; Chen TC; Hu FC
Endocr Pract; 2023 Feb; 29(2):89-96. PubMed ID: 36396015
[TBL] [Abstract][Full Text] [Related]
29. Response to methimazole in Graves' disease. The European Multicenter Study Group.
Benker G; Vitti P; Kahaly G; Raue F; Tegler L; Hirche H; Reinwein D
Clin Endocrinol (Oxf); 1995 Sep; 43(3):257-63. PubMed ID: 7586593
[TBL] [Abstract][Full Text] [Related]
30. Evidence for higher success rates and successful treatment earlier in Graves' disease with higher radioactive iodine doses.
Sztal-Mazer S; Nakatani VY; Bortolini LG; Boguszewski CL; Graf H; de Carvalho GA
Thyroid; 2012 Oct; 22(10):991-5. PubMed ID: 22953990
[TBL] [Abstract][Full Text] [Related]
31. Correlation of radioiodine doses for 6-hr and 24-hour iodine-131 thyroid uptake values for Graves' hyperthyroidism.
Horn-Lodewyk J
Endocr J; 2019 Dec; 66(12):1047-1052. PubMed ID: 31391354
[TBL] [Abstract][Full Text] [Related]
32. Cancer Risk in Graves Disease with Radioactive
Kim KJ; Choi J; Kim KJ; Song E; Yu JH; Kim NH; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG
J Nucl Med; 2024 May; 65(5):693-699. PubMed ID: 38548348
[TBL] [Abstract][Full Text] [Related]
33. [The effect of propylthiouracil on the efficacy of radioiodine (I-131) therapy in graves hyperthyroidism].
de Souza MV; Buescu A; Vaisman M; de Souza HF; Luiz RR
Arq Bras Endocrinol Metabol; 2006 Dec; 50(6):1088-95. PubMed ID: 17221116
[TBL] [Abstract][Full Text] [Related]
34. Radioiodine-Induced Salivary Gland Damage Detected by Ultrasonography in Patients Treated for Papillary Thyroid Cancer: Radioactive Iodine Activity and Risk.
Horvath E; Skoknic V; Majlis S; Tala H; Silva C; Castillo E; Whittle C; Niedmann JP; González P
Thyroid; 2020 Nov; 30(11):1646-1655. PubMed ID: 32370663
[No Abstract] [Full Text] [Related]
35. The adjunctive use of carbimazole during radioactive iodine treatment reduces the cure rate of Graves' disease.
Docrat F; Mokoena T; Karusseit VOL; Ankrah AO
S Afr Med J; 2021 Feb; 111(2):176-179. PubMed ID: 33944730
[TBL] [Abstract][Full Text] [Related]
36. Clinical course of pediatric and adolescent Graves' disease treated with radioactive iodine.
Pinto T; Cummings EA; Barnes D; Salisbury S
J Pediatr Endocrinol Metab; 2007 Sep; 20(9):973-80. PubMed ID: 18038706
[TBL] [Abstract][Full Text] [Related]
37. Time to Normalization and Sustainable Normal Serum Thyrotropin Concentrations in Patients with Hyperthyroidism: Comparison of Methimazole and Radioactive Iodine Treatments.
Azizi F; Saadat N; Abdi H; Mehran L; Masoumi S; Takyar MA; Amouzegar A
Endocr Pract; 2022 Nov; 28(11):1140-1145. PubMed ID: 35948251
[TBL] [Abstract][Full Text] [Related]
38. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment.
Stan MN; Durski JM; Brito JP; Bhagra S; Thapa P; Bahn RS
Thyroid; 2013 May; 23(5):620-5. PubMed ID: 23205939
[TBL] [Abstract][Full Text] [Related]
39. Thyroid volume is the key predictor of hyperthyroidism remission after radioactive iodine therapy in pediatric patients.
Sheremeta M; Korchagina M; Trukhin A; Nagaeva E; Bezlepkina O; Peterkova V
Eur J Pediatr; 2023 Nov; 182(11):4931-4937. PubMed ID: 37606704
[TBL] [Abstract][Full Text] [Related]
40. Radioiodine Therapy-Induced Conversion of Toxic Adenoma to Graves' Disease.
Rehman A; Obici S; Yaqub A
Cureus; 2020 Jun; 12(6):e8683. PubMed ID: 32699683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
